Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Inflammation Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for ANPEP (CD13) drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ANPEP ECD-Fc / Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View ANPEP Products |
| Gene Delivery | ANPEP Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Essential for membrane conformation preservation. |
View ANPEP Products |
| Benchmark Ab | Anti-ANPEP Clinical Benchmark Control Recombinant positive control for assay standardization. |
View ANPEP Products |
| Validator | ANPEP siRNA Set For knockdown verification and specificity screening. |
View ANPEP Products |
| Related Target: CD33 | Synergistic target for Acute Myeloid Leukemia (AML) dual-targeting strategies. | View CD33 Products |
| Related Target: VEGFA | Key partner in angiogenesis pathways and tumor microenvironment regulation. | View VEGFA Products |
| Related Target: DPP4 | Complementary ectoenzyme target; counter-screening for selectivity. | View DPP4 Products |
| Related Target: ENPEP | Closest homolog; essential for off-target liability assays. | View ENPEP Products |
| Related Target: FAP | Tumor microenvironment protease for dual-targeting strategies. | View FAP Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species cyno/mouse/human evaluation | Human, Mouse, and Cyno ortholog proteins available with >95% purity for cross-reactivity SPR profiling. Sequence Verified by Mass Spec. |
| Enzymatic assay stability & conformation | HEK293 expressed antigens ensure native glycosylation patterns crucial for metalloprotease structural integrity. |
| Internalization efficiency (ADC development) | Lentivirus-based stable cell lines preserving native recycling kinetics; high-purity ECD-Fc for pre-binding saturation studies. |
| Enzymatic selectivity (small molecule inhibitors) | Homolog panel (ANPEP, ENPEP, DPP4, MME, ACE2) with sequence verified identity; active-site accessibility confirmed. |
| Lack of reliable controls | Sequence-verified clinical benchmark recombinant antibodies included for reliable assay calibration. |
| Off-target false positives | Validated siRNA sets included for robust specificity checks and background elimination. |
Live ANPEP/CD13 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (ANPEP)
- ➤ View Active Clinical Trials (CD13)
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The race for ANPEP (CD13) therapeutics is intensifying, with major players shifting focus from traditional small molecule aminopeptidase inhibitors to targeted biological modalities like ADCs, NGR-peptide conjugates, bispecifics, and radioligands. As first-generation therapies reach the clinic, the next wave of R&D is targeting the specific conformational states of CD13 found on tumor neovasculature and leukemic blasts, driving the need for highly specific binder generation, conditional activation strategies in the tumor microenvironment, and combination regimens with immune checkpoint blockade. Overcoming antigen heterogeneity and on-target off-tumor toxicity (particularly in gut and kidney) remains critical.
Competitive Modality & Indication Snapshot
| Modality | Representative Focus | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Peptide-Drug Conjugates (PDC) / NGR | NGR-TNF, NGR-Radioligands | Solid Tumors, Angiogenesis | Receptor binding assay (need high-purity ECD-Fc with preserved binding sites) |
| ADC / Bispecifics | CD13/CD33 bispecifics, CD13-directed ADC | Acute Myeloid Leukemia (AML), NSCLC, Ovarian Solid Tumors | Internalization assay (need lentivirus-generated stable cell lines); heterodimer validation (cross-reactive Abs) |
| Small Molecule Inhibitors | Next-gen aminopeptidase inhibitors, Bestatin derivatives | Inflammatory diseases, Myeloid Leukemia | Selectivity assay (need catalytic mutant vs WT proteins as controls; homolog panel for off-target assessment) |
| CAR-T Therapy | CD13-directed cellular therapy | Relapsed/Refractory AML | Flow cytometry validation (need strict endotoxin-controlled antigens) |